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Abstract 
Background:  
Detection and treatment of heart failure (HF) can improve quality of life and reduce premature 
mortality. However, symptoms such as breathlessness are common in primary care, have a variety of 
causes and not all patients require cardiac imaging. In systems where healthcare resources are limited, 
ensuring those patients who are likely to have HF undergo appropriate and timely investigation is 
vital. 
Design: A decision tree was developed to assess the cost-effectiveness of using the MICE (Male, 
Infarction, Crepitations, Edema) decision rule compared to other diagnostic strategies to identify HF 
patients presenting to primary care. 
Methods: Data from REFER (REFer for EchocaRdiogram), a HF diagnostic accuracy study, was 
used to determine which patients received the correct diagnosis decision. The model adopted a UK 
National Health Service (NHS) perspective.  
Results: The current recommended National Institute for Health and Care Excellence (NICE) 
guidelines for identifying patients with HF was the most cost-effective option with a cost of £4,400 
per Quality Adjusted Life Year (QALY) gained compared to a “do nothing” strategy. That is, patients 
presenting with symptoms suggestive of HF should be referred straight for echocardiography if they 
had a history of myocardial infarction or if their NT-proBNP level was ≥400pg/ml. The MICE rule 
was more expensive and less effective than the other comparators. Base-case results were robust to 
sensitivity analyses.  
Conclusions:  This represents the first cost-utility analysis comparing HF diagnostic strategies for 
symptomatic patients. Current guidelines in England were the most cost-effective option for 
identifying patients for confirmatory HF diagnosis. The low number of HF with Reduced Ejection 
Fraction patients (12%) in the REFER patient population limited the benefits of early detection. 
Abstract word count: 245 
Keywords: Medical Economics; Economic Model; Cost Benefit Analysis; natriuretic peptide; general 
practice 
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INTRODUCTION 
Heart failure (HF) is a common clinical condition which is associated with major impact for patients 
and high costs for health systems, but is not easy to diagnose accurately or early in primary care.1-3  
 
The main symptoms suggestive of HF are shortness of breath, tiredness and swollen ankles but these 
complaints are common in primary care and most patients presenting with them will not have HF.4 
Furthermore, referring all symptomatic patients on for confirmatory investigations, such as 
echocardiography, is expensive. However, early detection of HF is important since evidence-based 
therapies can substantially improve quality of life, reduce premature mortality, and reduce avoidable 
hospital admissions.5, 6 The optimal cost-effective strategy for diagnosing HF patients at primary care 
level is not known.   
 
There is a paucity of data on diagnostic strategies in patients presenting in primary care with 
symptoms suggestive of HF where the population are rigorously phenotyped for HF. Economic 
analyses of diagnostic triage for this patient population are rarer still, but the REFER (REFer for 
EchocaRdiogram) study provides appropriate data to undertake an economic evaluation. 
 
REFER7 was a prospective, observational, diagnostic validation study of the MICE (Male, Infarction, 
Crepitations, Edema) clinical decision rule – with natriuretic peptide testing–for diagnosing HF in 
primary care. The full methods for the study have been previously published elsewhere.8 The clinical 
decision rule was developed from an Individual Patient Database meta-analysis of epidemiological 
studies of HF screening in primary care.9 
 
Briefly, primary care patients aged 55 years or over presenting to their GP with symptoms suggestive 
of HF were recruited across 28 Central England practices in the UK. All consenting patients 
underwent a full clinical assessment, which included a NT-pro B-type natriuretic peptide (NT-
proBNP) test, an echocardiogram and quality of life questionnaire, at a research clinic within one 
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week of recruitment. Follow-up quality of life and resource use questionnaires were mailed to the 
patients at six and twelve months after attending the clinic. 
 
The 304 patients included in the  REFER study had the following characteristics: mean age of 73.9 
years, White ethnicity (70.4%), Male (40.8%), history of Myocardial Infarction (11.2%), Basal 
Crepitations (5.3%), Ankle oedema (81.6%), Lethargy (74.3%) and had a median NT-proBNP of 
214pg/ml (IQR 79pg/ml -494 pg/ml).  
 
The diagnosis of ‘heart failure’ or ‘no heart failure’ was determined by an expert panel of 
cardiologists using the European Society of Cardiology (ESC) 2012 definition.5 Clinical information, 
including the variables of the MICE rule and NT-proBNP level, was presented in stages to quantify 
any incorporation bias.  
 
The aim of this study was to assess the cost-effectiveness of using the MICE clinical decision rule in 
HF diagnosis in Primary Care from a National Health Service (NHS) and Personal Social Services 
perspective. To do so, a decision tree was developed comparing different diagnostic strategies against 
the clinical decision rule. The economic analysis utilized the REFER dataset to determine which 
symptomatic patients received the correct diagnosis decision. The economic evaluation took a lifetime 
horizon and all costs and outcomes were discounted at an annual rate of 3.5% as recommended by the 
National Institute of Health and Care Excellence (NICE).10 
 
METHODS 
The six comparators are described below. Since the MICE rule has lower and upper cut-offs for the 
NT-proBNP referral levels, we treated them as two different diagnostic comparators: MICE upper 
cut-offs levels, and MICE lower cut-off levels. Strategies differed in terms of immediate actions. All 
patients with true HF who were not referred at this stage were assumed to return six months later and 
such patients will be referred immediately for echocardiography. 
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Economic evaluation diagnostic pathways 
MICE clinical decision rule 
The MICE clinical decision rule states a patient presenting with HF symptoms at the GP will be 
referred straight for echocardiography if the patient has either a history of Myocardial Infarction (MI), 
or basal crepitations, or is a male with ankle oedema. Otherwise a NT-proBNP test is carried out and 
the patient is referred straight for echocardiography if the test results are above one of three cut-offs 
set by gender/symptoms recorded in the clinical rule (where the upper MICE NT-proBNP cut-off 
levels are in parentheses): 
• A female patient without ankle oedema should be referred if NT-proBNP is ≥620pg/ml 
(1060pg/ml),or 
• A male patient without ankle oedema should be referred if NT-proBNP is ≥390pg/ml 
(660pg/ml),or 
• A female patient with ankle oedema should be referred if NT-proBNP is ≥190pg/ml 
(520pg/ml)  
 
NICE recommended strategy 
NICE guidelines for the management of chronic HF6 suggests that a patient presenting with symptoms 
suggestive of HF should be referred straight for echocardiography if they have a history of MI. 
Otherwise a NT-proBNP test should be carried out and patient referred for an echocardiograph if the 
NT-proBNP level is ≥400pg/ml.  
 
Echo all strategy 
With the Echo all strategy, all patients presenting with HF symptoms at the GP will be referred 
straight for echocardiography. We make a simplifying assumption that there will be no problems with 
access to echocardiography.  
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NT-proBNP 125 strategy 
With the NT-proBNP 125 strategy, all patients presenting with HF symptoms at the GP will have a 
NT-proBNP test carried out and the patient is referred for echocardiography if their NT-proBNP level 
is ≥125pg/ml. 
 
Do nothing strategy 
With the do nothing strategy, no patients presenting with HF symptoms at the GP will be referred 
straight for echocardiography nor undergo a NT-proBNP test. This option was added in for 
completeness. 
 
A decision tree, presented in TreeAgePro 2014 (TreeAge Software, Williamstown, MA) and 
developed in Excel, was structured to represent the various diagnostic strategies (Figure 1). A 
decision tree was appropriate here as the comparators diverge with regard to immediate actions. 
Branch probabilities were estimated from the REFER dataset. To ensure correct representation of the 
statistical uncertainty in the model, patients were categorised into groups (Appendix Table 1), on the 
principle that two patients would be in the same group if and only if they follow the same pathway in 
all strategies considered. For example, consider four patients of the same sex and with the same 
clinical signs, with no previous MI, but with NT-proBNP at 110pg/ml (A), 220pg/ml (B), 330pg/ml 
(C), and 440pg/ml (D). Under the “NT-proBNP 125” strategy, patients B, C and D would be referred 
for echocardiography, but A would not, while under the NICE strategy, only patient D would be 
referred. However, no strategy in the model has a cut-off between 220pg/ml and 330pg/ml, so patients 
B and C can be in the same group.  
 
The methodology behind the benefits of each strategy was drawn largely from a previous HF Health 
Technology Assessment (HTA) report.9 We assumed a confirmed HF diagnosis leads to patients 
being initiated on HF drug treatment if they have HF with Reduced Ejection Fraction (HFREF). 
Current trials do not suggest a survival advantage of angiotensin converting-enzyme inhibitors 
(ACEIs) or Beta-Blockers for HF patients with preserved ejection fraction (HFPEF).11 Thus, the 
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benefits from early detection of HF were weighted by the number of HF patients in the population 
(12%) that have a reduced ejection fraction. 
 
The type of HF drug and dose was obtained from a cohort study of patients treated for HF in primary 
care; 36.6% of patients were treated with Beta-Blockers, 58.9% of patients were treated with ACEIs, 
and 13.4% of patients were treated with angiotensin receptor blockers (ARBs).12 Patients can be on 
more than one HF drug therapy; to determine the proportion of patients on ACEI but not on Beta-
Blockers (not reported), we took a simple average of upper bound and lower bound range of the 
possible values (36.3%). 
 
HF treatment initiation due to correct early detection was assumed to have a survival benefit for the 
HF patient versus a missed HF diagnosis. A missed HF diagnosis was assumed to delay the diagnosis 
by six months. Delayed diagnosis patients were assumed to incur a further GP visit and an 
echocardiogram to confirm the diagnosis. After six months, the patient was put on treatment and 
thereafter has the same survival probability as someone who was already on treatment.  
 
We took the survival data from diagnosis of HF in patients in the Framingham heart study13 to be the 
patient’s prognosis without drug therapy. A meta-analysis indicated that beta-blockers versus placebo 
gave a hazard ratio of 0.73 (95% confidence interval 0.67-0.80) for all-cause mortality, 95% of these 
beta-blockers patients were also on ACEI/ARBs.14 The results of a systematic review showed that the 
mortality odds ratio for patients taking ACEI compared to a placebo was 0.80 (95% confidence 
interval 0.74–0.87).15 A Cochrane review found no significant effect of ARBs on mortality and, 
therefore, we make a conservative assumption that patients on ARBs only have the same survival rate 
as untreated patients.16  
 
Survival data and drug efficacies were used to plot gender-specific survival curves for the untreated 
patients and patients on different drug therapies (assuming no temporal changes in drug efficacy). The 
curves were extended beyond the ten year survival data via linear extrapolation to achieve a lifetime 
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horizon. Patients who were put on treatment earlier due to correct detection (Treat early) and  patients 
with a delayed diagnosis (Treat late) were weighted by the proportion of patients on the different drug 
therapies. Survival benefit due to early treatment was the area between the treated early and treated 
late curves. 
 
Patients with HF in the REFER study that answered the six months follow up questionnaire, scored 
with UK tariffs,17  gave an average EuroQol 5 dimensions (EQ-5D) score of 0.615 (standard deviation 
of 0.31). Discounted quality adjusted life year gain can be estimated from the product of the EQ-5D 
and the discounted life years gained.  
 
Early detection of HF also has the benefit of a reduction in hospitalisations. Patients on beta-blockers 
versus placebo have a hazard ratio of 0.71 (95% CI 0.65-0.77) for first HF related hospital 
admission.14 Similarly, treatment with ACEIs reduces the likelihood of a hospital admission with an 
odds ratio of 0.67 (95% CI 0.61-0.74).15 
 
For model purposes, we were interested in the increased rate of admission into hospital for an 
untreated population due to a six month delay in a HF diagnosis. Firstly, we take a previously 
calculated probability of admission if treated of 41.3%.9 Using the odds ratio of hospital admission 
with ACEIs treatment, the rate of admission within six months if untreated is 0.62. Assuming a 
constant hazard ratio for treatment with Beta-Blockers over the six months, the rate of admission 
within six months if untreated is 71.2%. A simple average was taken to calculate the estimated rate of 
admission with six months if untreated (66.4%). Thus, the increased number of hospitalization cases if 
untreated is 25.1%. This was then weighted by the number of HFREF patients in the population as 
only these patients receive prognostic benefit from treatment. 
 
Costs were inflated to 2013/2014 prices using the hospital & community health service (HCHS) pay 
and prices index where applicable.18 The cost of a General Practitioner appointment (£46) was taken 
from Unit Costs.18 The cost of an avoidable HF hospital admission was calculated from weighted 
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average reference costs of HF admissions (£2107).19 An echocardiography referral cost was taken 
from the Payment by Results mandatory tariff,20 consisting of a simple echocardiogram and a 
consultant-led outpatient first attendance (totalling £241). The cost of a NT-proBNP test (£30) was 
taken from a NICE costing report.21 
 
The early treatment HF drug cost was estimated from the resource usage combined with prices from 
the British National Formulary (BNF).22 Since the typical drug dose for a HF patient is variable, we 
pragmatically assumed that same percentage of patients reach the target dose −as defined by the 2005 
ESC guidelines in their study− and the remainder achieve half the target dose. Where the drug listed 
was not recommended by the 2012 ESC guidelines,5 the target dose indication for HF in the BNF was 
used. For the base-case analysis, the cost of the generic drugs for the first six months was used (£10); 
the cost of the equivalent therapy with branded drugs was substituted for the sensitivity analysis 
(£30).  
 
Results were presented as the costs and effects of each strategy and ordered by increasing cost. 
Effectiveness was measured in quality adjusted life years (QALYs). The incremental analysis was 
designed to generate the cost per additional QALY gained for using one diagnostic strategy over 
another. Cost-effectiveness was assessed in relation to the lower NICE threshold of £20,000 per 
QALY gained.23 More costly and less effective options were excluded from consideration 
(dominated). Likewise options that suffer from extended dominance were removed from 
consideration. Extended dominance occurs when an option would be dominated compared to a mixed 
option of two other strategies.   
 
Sensitivity analysis was performed to assess model robustness. For the deterministic sensitivity 
analysis, the following scenarios were explored: 
1. Doubling and halving the cost of a NT-proBNP test. 
2. Altering the drug efficacies to their lower and upper confidence intervals 
respectively. 
11 
 
3. Substituting in branded drug therapy prices for generic drug therapy prices. 
4. Increasing the proportion of HFREF patients from 12% to 24%, 50%, and 100% 
respectively.  
 
For the probabilistic sensitivity analysis, distributions were attached to the clinical parameters, drug 
efficacies, and HF utility (Table 1). The model was run for 10,000 iterations and the results presented 
as a cost-effectiveness acceptability frontier (CEAF). The CEAF shows, across a range of different 
cost-effectiveness thresholds, the uncertainty associated with the optimal diagnostic option.   
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Table 1 Parameter distributions for Probabilistic Sensitivity Analysis 
Parameters Distribution Parameter estimates* Deterministic value** Source 
Patients true diagnosis Beta α = 104 
β = 200 
34.2% REFER 
dataset7 
Heart Failure utility  
(EuroQol-5 Dimensions) 
Beta α = 0.95 
β = 0.59 
0.62 REFER 
dataset7 
Beta-blockers  effect on 
mortality 
Log normal µ = -0.31 
σ = 0.05 
0.73 Kotecha and 
colleagues12 
Beta-blockers effect on 
hospitalization risk 
Log normal µ = -0.34 
σ = 0.04 
0.71 Kotecha and 
colleagues12 
ACEI effect on mortality Log normal µ=  -0.22 
σ = 0.04 
0.80 Flather and 
colleagues13 
ACEI effect on 
hospitalization risk 
Log normal µ = -0.40 
σ = 0.05 
0.67 Flather and 
colleagues13 
Patients on each drug therapy 
(beta-blockers, ACEI, Other) 
Dirichlet (α1,α2,α3)= 
(3403,3378,1908) 
(36.5%,36.3%,6.1%) Calvert and 
colleagues10 
*For the lognormal distributions, µ is the mean and σ is the standard deviation of the underlying normal distribution which 
gives the logarithm of the model parameter 
** The deterministic value is the mean except in the case of the lognormal distributions where the median is given.  
ACEI, angiotensin converting-enzyme inhibitors 
 
 
Positive count data in patient groups formed the parameters for the Dirichlet distribution (Appendix 
Table 1). On each replication a vector of probabilities was sampled from the appropriate distribution. 
Where there was no count data (no patients) in a group, no distribution was attached. Treating the 
probability as fixed for these empty patient groups will slightly underestimate the uncertainty in the 
model rather than the alternative of adding an occurrence and positively biasing the amount of 
occurrences.24  
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RESULTS 
Costs and effectiveness of each strategy are shown in Table 2. The clinical decision rules of MICE 
were dominated by the other strategies. Given a willingness to pay (WTP) threshold of 
£20,000/QALY, only the NICE strategy was cost-effective.  
Table 2 Base-case results 
Strategy Costs 
(£) 
QALY gain compared 
to “Do nothing” 
Cost per QALY Proportion of 
True HF detected 
Proportion of 
Not HF ruled out 
Do nothing 119 -  0.00% 100.00% 
NICE strategy 142 0.0051 £4,400 78.85% 63.50% 
MICE upper cut-off 167 0.0050 (dominated) 81.73% 84.00% 
MICE lower cut-off 191 0.0057 (extended dominance) 90.38% 45.50% 
NT-proBNP 125 196 0.0059 £69,000 94.23% 49.00% 
Echo all 241 0.0063 £125,100 100.00% 0.00% 
QALY, Quality-Adjusted Life Year; HF, Heart Failure; NICE, National Institute for Health and Care Excellence; Cost per 
QALY rounded to the nearest multiple of £100/QALY 
 
Sensitivity analyses (Table 3) showed that NICE strategy remained the most cost-effective option for 
each scenario except where the proportion of HFREF changed to 50% and above. When the 
proportion of HFREF patients was 50%, the NT-proBNP 125 strategy became cost-effective, and 
when this proportion reaches 100%, it became cost-effective to refer all patients for immediate 
echocardiography.   
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Table 3 Deterministic Sensitivity Analysis Scenario Results 
 
NICE Strategy versus do 
nothing 
NT-proBNP 125 
versus NICE strategy 
Echo all versus 
NT-proBNP 125 
Scenario1 Cost per additional Quality-Adjusted Life Year (QALY) 
Base case results £4,400 £69,000 £125,100 
Double NT-proBNP test cost £9,600 £73,300 £42,100 
Half  NT-proBNP cost £1,800 £66,800 £166,600 
Branded drug price therapy £9,700 £68,900 £125,200 
Higher drug efficacy for mortality £3,300 £52,000 £94,200 
Lower drug efficacy for mortality £6,600 £104,200 £189,100 
Proportion of HFREF patients doubled to 
24% £600 £32,900 £60,900 
Proportion of HFREF patients increased to 
50%  Dominates Do Nothing £13,300 £26,400 
Proportion of HFREF patients increased to 
100% Dominates Do Nothing £5,000 £11,600 
1.The MICE cut-off options were excluded from the table as they remain dominated in each scenario 
NICE, National Institute for Health and Care Excellence; HFREF, Heart Failure with Reduced Ejection Fraction; Cost per 
QALY rounded to the nearest multiple of £100/QALY 
 
 
Figure 2 illustrates the overall uncertainty related to the optimal decision across a range of plausible 
WTP values, where WTP was measured in cost per additional QALY. At £20,000/QALY, the 
likelihood of the NICE strategy being the optimal option (i.e. highest Net Monetary Benefit) is 99.9%. 
As the WTP threshold increases beyond £68,000, the NT-proBNP 125 option becomes more likely to 
be the optimal option. 
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DISCUSSION 
Results indicate that, for the REFER population, current NICE guidelines on diagnosing HF represent 
the most cost-effective strategy compared to the MICE decision rules and other diagnostic strategies. 
That is, patients presenting with symptoms suggestive of HF should be referred straight for 
echocardiography if they have a history of MI or if their NT-proBNP level is ≥400pg/ml. The MICE 
decisions rules were not cost-effective due to dominance by the other strategies. The cost-
effectiveness results were robust to deterministic and probabilistic sensitivity analysis.  
 
Modest effectiveness gains for each strategy can be largely explained by the REFER study patient 
characteristics. The modelled benefits of early detection of HF and the subsequent prognostic window 
of improvement (treated early versus treated late) were limited since only 12% of the REFER HF 
participants were HFREF patients. We modelled no benefits from earlier detection in the 88% of the 
REFER HF population detected with non-HFREF. This is an appropriate conservative assessment but 
it is unlikely that these patients will derive zero benefit from detection. Although drug trials in HFPEF 
have failed to prove prognostic benefit, there is still a need for diagnosis to allow clinicians to explain 
and manage patients symptoms, and for ongoing research to find novel approaches to HFPEF 
treatment. 
 
Increasing the proportion of HREF patients raised the total QALYs of each diagnostic strategy due to 
the higher rewards of a correct early detection. Most population surveys suggest that approximately 
half of HF patients suffer HFREF, in contrast to the 12% detected in REFER, and in this sensitivity 
scenario the dominant cost-effective strategy is the reduced NT-proBNP cut-off for referral for 
echocardiography of 125pg/ml rather than the NICE level of 400pg/ml. Echo all strategy became the 
most cost-effective option when we assume all the HF patients will receive prognostic benefit from 
treatment. However, it must be acknowledged that there may be practical barriers to the 
implementation of such a strategy. Delays to echocardiograms may potentially offset the advantage of 
early detection and referring all patients for an echocardiogram will put pressure on local diagnostic 
services.  
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Since NT-proBNP came into more general use in the healthcare system, the costs per test may have 
dropped so the cost-effectiveness of natriuretic peptide testing may be underestimated here. Halving 
the cost of a NT-proBNP test made the NT-proBNP strategies more cost-effective compared with the 
‘echo all’ and the ‘do nothing’ strategies.  
 
HF therapy drug mix related to a 2009 publication from older data.12 As it is likely that there are 
higher drug rates nowadays, the assumed proportion of patients on ACEIs and Beta-Blockers may be 
underestimated so the benefit of early diagnosis may be greater. Since the clinical study has been 
carried out, guidelines on the diagnosis and treatment of heart failure has been updated;25 hence 
diagnosis of HF is according to 2012 definitions and HF with Mid-Range Ejection Fraction was not 
considered as a third group as in the 2016 guidelines.  
 
This is the first cost utility analysis to compare a representative range of strategies for diagnosis in this 
patient population, making comparison to other studies difficult. Previous studies26, 27 have looked at 
the costs of using NT-proBNP as a means to rule out HF and to reduce the levels of echocardiography 
referrals but these cannot address the question of an optimal cost-effective diagnostic strategy and 
also did not place a cost on a missed HF diagnosis. 
 
The main strength of this analysis is that the diagnostic accuracy of the various strategies tested was 
calculated based on a consistent primary dataset. This was reinforced by the process used in the 
clinical study to develop an appropriate gold standard against which to compare imperfect diagnostic 
strategies. The main limitations are that the REFER dataset may not be typical of patients in other 
geographic areas, and the need for assumptions in projecting the lifetime costs and outcomes from 
correct diagnosis. The low prevalence of HFREF in the REFER patient population may be due to  
patients with HFREF being more likely to present themselves directly to secondary care rather than 
primary care.7 The lack of representation of HFREF patients compared with other studies may 
represent a selection bias affecting the final results.  
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Overall, this analysis provides evidence based on primary data that the current strategy recommended 
by NICE is appropriate. However, based on sensitivity analyses, as the proportion of HFREF 
increases from the 12% seen in REFER, it becomes more cost-effective to change the NICE NT-
proBNP threshold from 400pg/ml to 125pg/ml. 
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Appendix 
Appendix Table 1 REFER Patient characteristics 
 
Clinical Parameters  n (%) Heart Failure 
(n = 104) 
No Heart Failure 
(n= 200) 
Patients with previous MI with NT-proBNP levels less than 125pg/ml 1 (1.0) 10 (5.0) 
Patients with previous MI with NT-proBNP levels greater than or equal to 125pg/ml 16 (15.4) 7 (3.5) 
Patients with basal crepitations without previous MI with NT-proBNP levels less 
than 125pg/ml 
0 (0.0) 5 (2.5) 
Patients with basal crepitations without previous MI with NT-proBNP levels 
between 125pg/ml and 399pg/ml 
0 (0.0) 4 (2.0) 
Patients with basal crepitations without previous MI with NT-proBNP levels equal 
to or above 400pg/ml  
3 (2.9) 2 (1.0) 
Male patients with ankle oedema without basal crepitations or previous MI with NT-
proBNP less than 125pg/ml 
0 (0.0) 22 (11.0) 
Male patients with ankle oedema without basal crepitations or previous MI with NT-
proBNP levels between 125pg/ml and 399pg/ml 
4 (3.8) 17 (8.5) 
Male patients with ankle oedema without basal crepitations or previous MI with NT-
proBNP levels equal to or above 400pg/ml  
22 (21.2) 5(2.5) 
Female patients without ankle oedema without the MICE criteria with NT-proBNP 
levels less than 125pg/ml 
0 (0.0) 9 (4.5) 
Female patients without ankle oedema without the MICE criteria with NT-proBNP 
levels between 125pg/ml and 399pg/ml 
0 (0.0) 6 (3.0) 
Female patients without ankle oedema without the MICE criteria with NT-proBNP 
levels between 400pg/ml and 619pg/ml 
0 (0.0) 2 (1.0) 
Female patients without ankle oedema without the MICE criteria with NT-proBNP 
levels between 620pg/ml and 1059pg/ml 
1 (1.0) 0 (0.0) 
Female patients without ankle oedema without the MICE criteria with NT-proBNP 
levels equal to or above 1060pg/ml 
0 (0.0) 0 (0.0) 
Female patients with ankle oedema without the MICE criteria with NT-proBNP 
levels less than 125pg/ml 
4 (3.8) 43 (21.5) 
21 
 
Female patients with ankle oedema without the MICE criteria with NT-proBNP 
levels between 125pg/ml and 189pg/ml 
3 (2.9) 15 (6.5) 
Female patients with ankle oedema without the MICE criteria with NT-proBNP 
levels between 190pg/ml and 399pg/ml 
4 (3.8) 31 (15.5) 
Female patients with ankle oedema without the MICE criteria with NT-proBNP 
levels between 400pg/ml and 519pg/ml 
4 (3.8) 5 (2.5) 
Female patients with ankle oedema without the MICE criteria with NT-proBNP 
levels equal to or above 520pg/ml  
30 (28.8) 0 (0.0) 
Male patients without ankle oedema without the MICE criteria with NT-proBNP 
levels less than 125pg/ml 
1 (1.0) 9 (4.5) 
Male patients without ankle oedema without the MICE criteria with NT-proBNP 
levels between 125pg/ml and 389pg/ml 
2 (2.0) 7 (3.5) 
Male patients without ankle oedema without the MICE criteria with NT-proBNP 
levels between 390pg/ml and 399pg/ml 
1 (1.0) 0 (0.0) 
Male patients without ankle oedema without the MICE criteria with NT-proBNP 
levels between 400pg/ml and 659pg/ml 
2 (2.0) 0 (0.0) 
Male patients without ankle oedema without the MICE criteria with NT-proBNP 
equal to or above 660pg/ml  
6 (5.8) 1 (0.50) 
MI, Myocardial Infarction 
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Appendix Table 2 Estimated undiscounted survival probabilities for male patients with heart failure 
on and off therapy 
Years Untreated ACEI BB Treated early Treated late 
0 1.00 1.00 1.00 1.00 1.00 
0.25 0.73 0.77 0.79 0.77 0.73 
0.5 0.68 0.72 0.75 0.72 0.68 
1 0.57 0.62 0.66 0.62 0.59 
2 0.46 0.52 0.57 0.52 0.49 
5 0.25 0.29 0.36 0.31 0.29 
10 0.11 0.13 0.20 0.15 0.14 
11 0.08 0.10 0.16 0.12 0.11 
12 0.05 0.07 0.12 0.08 0.07 
13 0.03 0.03 0.07 0.04 0.04 
14 0.00 0.00 0.02 0.01 0.00 
15 0.00 0.00 0.00 0.00 0.00 
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Appendix Table 3 Estimated undiscounted survival probabilities for female patients with heart failure 
on and off therapy 
Years Untreated ACEI BB Treated early Treated late 
0 1.00 1.00 1.00 1.00 1.00 
0.25 0.72 0.76 0.79 0.76 0.72 
0.5 0.69 0.74 0.77 0.74 0.69 
1 0.64 0.69 0.72 0.69 0.65 
2 0.56 0.61 0.65 0.61 0.58 
5 0.38 0.43 0.49 0.44 0.41 
10 0.21 0.25 0.32 0.26 0.25 
11 0.18 0.21 0.28 0.23 0.21 
12 0.14 0.17 0.24 0.19 0.17 
13 0.11 0.13 0.20 0.15 0.14 
14 0.07 0.09 0.15 0.11 0.10 
15 0.04 0.05 0.10 0.06 0.06 
16 0.01 0.01 0.02 0.01 0.01 
17 0.00 0.00 0.00 0.00 0.00 
 
 
 
